CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy ...

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...

Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated ...

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

Shares of pharmaceutical company Bristol Myers Squibb ($BMY) are up 4% on news that the U.S. Food and Drug Administration ...

While not a mind-blowing move, it is good to see that the Bristol-Myers Squibb Company (NYSE:BMY) share price has gained 22% in the last three months. But that doesn't help the fact that the three ...

Bristol Myers Squibb (BMY) ended the recent trading session at $49.95, demonstrating a +0.46% swing from the preceding day's closing price. This move lagged the S&P 500's daily gain of 1.01%.

8 analysts have expressed a variety of opinions on Bristol-Myers Squibb BMY over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed ...